Brain blood vessel dysfunction may precede the cognitive decline seen in Alzheimer's disease, yet the precise molecular trigger remained unclear until now. Understanding this vascular component could reshape how we approach dementia prevention and treatment strategies.
This investigation reveals that amyloid beta plaques deplete nicotinamide adenine dinucleotide (NAD+) in brain endothelial cells, creating a destructive cascade. When NAD+ levels drop, voltage-dependent anion channel 1 proteins clump together, causing mitochondrial DNA to leak into the cell cytoplasm. This triggers the cGAS/STING inflammatory pathway, pushing blood vessel cells into senescence while ramping up CD38 enzyme activity that further consumes remaining NAD+. These aged vessel cells then release inflammatory signals that activate nearby microglia through IL-6 signaling. Nicotinamide riboside supplementation in APP/PS1 mouse models restored mitochondrial integrity, suppressed the inflammatory cascade, and improved both vascular function and cognitive performance.
This work elegantly connects two major theories of Alzheimer's pathogenesis: vascular dysfunction and neuroinflammation. The finding that NAD+ depletion serves as the molecular bridge between amyloid pathology and blood-brain barrier breakdown represents a significant conceptual advance. Previous research has shown NAD+ decline with aging, but demonstrating its specific role in triggering endothelial senescence provides a mechanistic foundation for therapeutic intervention. The study's limitation lies in its reliance on mouse models, though the molecular pathways identified are highly conserved across species. If validated in human studies, NAD+ restoration through supplements like nicotinamide riboside could offer a preventive approach targeting vascular health before cognitive symptoms emerge.
